Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

19.11.2018 | short review | Ausgabe 1/2019 Open Access

memo - Magazine of European Medical Oncology 1/2019

A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2019
Autoren:
Hossein Taghizadeh, Katharina Lampichler, Andrea Beer, Matthias Preusser, MD, PhD Aysegul Ilhan-Mutlu

Summary

In this report, we present the medical history of a 30-year-old male patient with HER2- and PD-L1-negative metastasized adenocarcinoma of the gastric cardia, who received three cycles of pembrolizumab (200  mg every 2 weeks) after the failure of the first-line (1L) treatment with docetaxel, cisplatin, 5‑fluorouracil (DCF). A restaging computed tomography (CT) scan for the chest and abdomen revealed an apparent progressive disease; therefore, the treatment was terminated. Five months after the termination of the treatment, a new CT scan demonstrated a spontaneous treatment response although no treatment was given during this time period, indicating pseudo-progression of the tumor in the first restaging after three cycles of pembrolizumab. This finding is apparently due to the long-term sustainable immunological effects of pembrolizumab. The current report will present this rare case in more detail and summarize the closed and ongoing clinical trials of immunotherapy drugs in gastroesophageal cancer.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

memo - Magazine of European Medical Oncology 1/2019 Zur Ausgabe